Key result
SGLT2 inhibitors carry a ~21% adverse event rate in pediatric heart failure.
Why the study?
Although SGLT2 inhibitors are a foundational therapy for adult heart failure across the ejection fraction spectrum, their safety profile in children with heart failure had not been quantitatively synthesized.
What is the incidence of adverse events associated with SGLT2 inhibitors in pediatric patients with heart failure?
Meta-Analysis (n=573)
What is the incidence of adverse events associated with SGLT2 inhibitors in pediatric patients with heart failure?
SGLT2 inhibitors demonstrate a tolerable safety profile and favorable directional efficacy signals in pediatric heart failure, supporting the need for dedicated pediatric randomized trials.
Answers are grounded in this paper and cite their sources.
Acceptable adverse event rates support cautious monitoring in pediatric heart failure; leaves open randomized trials to confirm efficacy.
OBJECTIVE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become a foundational therapy for adult heart failure across the entire spectrum of ejection fraction, but their safety profile in children with heart failure has not been quantitatively synthesized. We conducted a systematic review and meta-analysis of proportions to summarize the incidence of adverse events associated with SGLT2 inhibitors in pediatric heart failure. STUDY DESIGN: In this systematic review and meta-analysis of proportions (PROSPERO CRD420261355711; PRISMA 2020), five databases were searched through June 2026 for studies of any design reporting adverse events among pediatric patients receiving an SGLT2 inhibitor for heart failure. Random-effects incidence estimates were pooled using logit-transformed proportions with restricted maximum-likelihood estimation and modified Hartung-Knapp-Sidik-Jonkman confidence intervals; risk of bias and GRADE certainty were assessed. RESULTS: Ten studies (573 unique children; 2023-2026) were included; eight studies (572 patients; maximum pooled denominator 474) were meta-analyzed, and one case report was summarized narratively. Dapagliflozin accounted for 94.1% of exposures. Study-level dapagliflozin doses ranged from 0.11 to 0.23 mg/kg/day, while the single cohort reporting empagliflozin used a median dose of 0.13 mg/kg/day. No regimen was derived from pediatric heart-failure pharmacokinetic data, and in the only cohort reporting a comparison, infants received a higher weight-normalized dose than older children (0.18 versus 0.16 mg/kg/day). Pooled incidences were: any adverse event 21.2% (95% CI 10.7-37.8%), acute kidney injury 10.7% (3.5-28.1%), urinary tract infection 7.8% (4.8-12.4%), treatment discontinuation 7.0% (4.5-10.6%), all-cause mortality 5.6% (2.4-12.5%), hypoglycemia 2.9% (0.9-9.3%), genital mycotic infection 2.7% (0.9-8.2%), and diabetic ketoacidosis 1.3% (0.4-3.9%). No deaths were attributed to therapy, and no cases of euglycemic ketoacidosis or Fournier gangrene occurred. Directional efficacy signals were consistently favorable, with left ventricular ejection fraction improving in five of six cohorts and natriuretic peptide levels declining across all seven in which they were assessed. CONCLUSIONS: SGLT2 inhibitors had a tolerable safety profile in pediatric heart failure, mirroring the adult experience. Adequately powered randomized trials with standardized adverse-event grading are needed. REGISTRATION: PROSPERO identifier no. CRD420261355711.
No takes yet. Share an insight, caveat, or question.
Cakan et al. (2026) conducted a meta-analysis in Pediatric heart failure (n=573). SGLT2 inhibitors (dapagliflozin, empagliflozin) was evaluated on Incidence of any adverse event (Pooled incidence 21.2%, 95% CI 10.7-37.8%). SGLT2 inhibitors in pediatric heart failure had a pooled adverse event incidence of 21.2%, with 10.7% acute kidney injury and 7.0% treatment discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: